GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Cyclically Adjusted PB Ratio

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Achillion Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Achillion Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Achillion Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Achillion Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Achillion Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Achillion Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2019 was:

Adj_Book=Book Value per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=1.553/108.3294*108.3294
=1.553

Current CPI (Sep. 2019) = 108.3294.

Achillion Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200912 0.038 91.111 0.045
201003 0.480 91.821 0.566
201006 0.327 91.962 0.385
201009 0.957 92.162 1.125
201012 0.866 92.474 1.014
201103 0.704 94.283 0.809
201106 1.320 95.235 1.502
201109 1.179 95.727 1.334
201112 1.017 95.213 1.157
201203 0.905 96.783 1.013
201206 0.738 96.819 0.826
201209 1.027 97.633 1.140
201212 0.905 96.871 1.012
201303 2.020 98.209 2.228
201306 1.831 98.518 2.013
201309 1.701 98.790 1.865
201312 1.580 98.326 1.741
201403 1.430 99.695 1.554
201406 1.288 100.560 1.388
201409 1.193 100.428 1.287
201412 1.385 99.070 1.514
201503 2.263 99.621 2.461
201506 2.050 100.684 2.206
201509 3.148 100.392 3.397
201512 3.291 99.792 3.573
201603 3.183 100.470 3.432
201606 3.067 101.688 3.267
201609 2.935 101.861 3.121
201612 2.922 101.863 3.108
201703 2.796 102.862 2.945
201706 2.651 103.349 2.779
201709 2.508 104.136 2.609
201712 2.353 104.011 2.451
201803 2.221 105.290 2.285
201806 2.125 106.317 2.165
201809 2.024 106.507 2.059
201812 1.918 105.998 1.960
201903 1.795 107.251 1.813
201906 1.668 108.070 1.672
201909 1.553 108.329 1.553

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Achillion Pharmaceuticals  (NAS:ACHN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Achillion Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 George Street, New Haven, CT, USA, 06511
Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.
Executives
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves director C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman director C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo director 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning officer: General Counsel 700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta officer: EVP, Chief Commercial Officer 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske officer: EVP, Chief Medical Officer 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton officer: Chief Financial Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande director, officer: Chief Executive Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian officer: Chief Medical Officer C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Headlines

From GuruFocus

Achillion Shareholders Approve Agreement to be Acquired by Alexion

By Marketwired Marketwired 12-19-2019